secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K/A
Filed at:   2026-10-05T11:21:13+00:00
Accession:  0001140361-26-038535
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 9.01, 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Processa's Vidya acquisition adds BTK inhibitor VT7208 plus a $200M private placement
--------------------------------------------------------------------------------

- On July 28, 2026 Processa acquired Vidya Therapeutics; VT7208, an oral CNS-penetrant BTK inhibitor, is now the lead asset in food allergy, chronic spontaneous urticaria and MS.
- Received $200M gross proceeds from private placement of non-voting convertible preferred stock; investors include Bain Capital Life Sciences, Janus Henderson, RA Capital and Cormorant.
- Phase 1 data: 5 mg single dose achieved >95% BTK target occupancy at 4 hours and >99% peak, sustained ~48 hours; 10 mg MAD dose hit 100% occupancy.
- Phase 1 trial in 24 healthy volunteers (5-60 mg) showed no dose-limiting toxicities, no serious adverse events, no treatment-related discontinuations and no liver-safety signal; DILI-risk score 2.1.
- Founder Sheila Gujrathi, M.D., who led ocrelizumab (Ocrevus) development at Roche, heads the team; company also continues legacy assets PCS499, PCS12852 and PCS11T.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000114036126038535/0001140361-26-038535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000114036126038535/ef20083140_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-038535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer